Global Infectious Disease Drug Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

The global infectious disease drug market is projected to grow at a CAGR of over 4% during the forecast period. Infectious diseases transfer from person to person, and bites of insects and animals, through ingestion of contaminated food or water or being exposed to organisms such as bacteria, viruses, parasites, and fungi in the surroundings. The factors that are supporting the growth of the infectious disease drug industry include the increased prevalence of diseases and continuous contributions by the key players in the global infectious diseases drug market. 

To Request a Sample of our Report on Global Infectious Disease Drug Market:  https://www.omrglobal.com/request-sample/infectious-disease-drug-market

Some of the key players operating in the market across the globe include Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA, among others. These key players are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to sustain in a competitive environment and gain maximum share in the global infectious disease drug market. 

In November 2019, Allergan Plc announced the achievement of the Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation for ATM-AVI by the US FDA for the treatment of various infectious diseases, such as ventilator-associated bacterial pneumonia (VABP)/ hospital-acquired bacterial pneumonia (HABP), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI).

In November 2019, Bayer AG expanded the 5-year collaboration with the World Health Organization (WHO) for the R&D activities on the infectious disease such as taeniasis and neurocystercosis, which are the major preventable cause of epilepsy. 

In May 2019, Celegen Corp. announced that it has received the Breakthrough Therapy designation to POMALYST (pomalidomide) from the US FDA for the treatment of HIV patients.

In June 2018, Gilead Sciences Inc. and Hookipa partnered and signed a licensing agreement for the development of immunotherapies against HIV and Hepatitis B. Through this agreement both the companies together manufacture arenavirus-based vectors for clinical development by Gilead Sciences Inc.

 Current Market Trends Covered in the Global Infectious Disease Drug Market Report:

·        Improved healthcare infrastructure along with various reimbursements is positively affecting the infectious disease drug industry.

·        Shifting of consumer preferences toward the use of personalized or precision medicines is expected to provide ample growth opportunities to the infectious disease drug market.

·        Antibacterial treatment type segment will have significant growth in the market.

·        Asia-Pacific region will register a significant growth rate in infectious disease drug market during the forecast period.

(Get 15% Discount on Buying this Report)

A full Report of Global Infectious Disease Drug Market is Available at:  https://www.omrglobal.com/industry-reports/infectious-disease-drug-market

Global Infectious Disease Drug Market - Segmentation 

 By Disease Type

·        Bacterial Disease

·        Viral Disease

·        Fungal Disease

·        Parasitic Disease

By Treatment Type

·        Antibacterial

·        Antiparasitic

·        Antiviral

·        Antifungal

·        Others 

Global Infectious Disease Drug Market – Segmentation by Region 

North America

·        United States

·        Canada

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan

·                  South Korea

·                  Rest of APAC

Rest of The World

·                  Latin America 

·                  Middle East & Africa

Company Profiles

·        AbbVie Inc.

·        Allergan Plc

·        Amgen Inc.

·        Bayer AG

·        BioCryst Pharmaceuticals, Inc.

·        Boehringer Ingelheim GmbH

·        Bristol-Myers Squibb Co.

·        Eli Lilly & Co.

·        F. Hoffmann-La Roche Ltd.

·        Gilead Sciences, Inc.

·        GlaxoSmithKline PLC

·        Johnson & Johnson Services, Inc.

·        Merck & Co. Inc.

·        Moderna Inc.

·        Novartis International AG

·        Novo Nordisk A/S

·        Pfizer Inc.

·        Sanofi SA

·        Takeda Pharmaceuticals Co. Ltd.

·        Teva Pharmaceuticals Industries Ltd.

Reasons to Buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @  https://www.omrglobal.com/report-customization/infectious-disease-drug-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404